ZA94372B - Therapeutic methods and delivery systems utilizing sex steroid precursors - Google Patents

Therapeutic methods and delivery systems utilizing sex steroid precursors

Info

Publication number
ZA94372B
ZA94372B ZA94372A ZA94372A ZA94372B ZA 94372 B ZA94372 B ZA 94372B ZA 94372 A ZA94372 A ZA 94372A ZA 94372 A ZA94372 A ZA 94372A ZA 94372 B ZA94372 B ZA 94372B
Authority
ZA
South Africa
Prior art keywords
delivery systems
therapeutic methods
systems utilizing
sex steroid
steroid precursors
Prior art date
Application number
ZA94372A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of ZA94372B publication Critical patent/ZA94372B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
ZA94372A 1993-01-19 1994-01-19 Therapeutic methods and delivery systems utilizing sex steroid precursors ZA94372B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US561993A 1993-01-19 1993-01-19

Publications (1)

Publication Number Publication Date
ZA94372B true ZA94372B (en) 1995-07-19

Family

ID=21716809

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94372A ZA94372B (en) 1993-01-19 1994-01-19 Therapeutic methods and delivery systems utilizing sex steroid precursors

Country Status (10)

Country Link
US (6) US5776923A (zh)
EP (1) EP1382340B1 (zh)
CN (3) CN1954804A (zh)
CA (1) CA2154161C (zh)
DK (1) DK1382340T3 (zh)
IL (5) IL181017A0 (zh)
MY (2) MY157883A (zh)
SK (1) SK286664B6 (zh)
UA (1) UA73911C2 (zh)
ZA (1) ZA94372B (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
AU8779898A (en) * 1997-08-11 1999-03-01 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
KR100302372B1 (ko) * 1998-07-24 2001-12-05 박상철 골다공증예방및치료제로서의디히드로에피안드로스테론유도체
US6726673B1 (en) * 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CN100544726C (zh) 1999-03-18 2009-09-30 基因实验室技术公司 Dhea制剂及方法
EP1187618A1 (en) * 1999-06-04 2002-03-20 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP1955700B9 (en) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (fr) * 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
FR2803519B1 (fr) * 2000-01-12 2002-03-22 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs et de ses derives pour ameliorer l'aspect papyrace de la peau
KR20020073566A (ko) * 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1315502B1 (en) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
PL360992A1 (en) * 2000-08-30 2004-09-20 Unimed Pharmaceuticals,Inc. Method of increasing testosterone and related steroid concentrations in women
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SI1347764T1 (sl) * 2000-12-22 2007-06-30 August Wolff Gmbh & Co Kg Arzenmittel Dr Gelni sestavek na alkoholni osnovi za zdravljenje hipogonadizma s trans-skrotalno aplikacijo
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
RU2297218C2 (ru) * 2001-07-09 2007-04-20 Зонаджен, Инк. Способы и материалы для лечения тестостероновой недостаточности у мужчин
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
FR2827764B1 (fr) * 2001-07-27 2005-08-19 Oreal Composition, notamment cosmetique, renfermant un steroide et un glycol
FR2828100B1 (fr) * 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
WO2003090754A1 (en) * 2002-04-23 2003-11-06 Sahltech I Göteborg AB Use of dhea for treatment of female hypopituitarism
KR100538386B1 (ko) * 2002-08-26 2005-12-27 메타볼랩(주) Ｉｌ-1 관련 질병 또는 질환의 치료용 약제학적 조성물
CN1726020A (zh) * 2002-10-16 2006-01-25 Gtx公司 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
PT1670433E (pt) 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20050239826A1 (en) * 2004-04-14 2005-10-27 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
BRPI0606528A8 (pt) * 2005-02-04 2018-03-13 Repros Therapeutics Inc composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2431042B1 (en) * 2005-03-24 2013-06-26 Emory University Methods for the treatment of central nervous system injury via a tapered administration protocol
CN101217874B (zh) * 2005-04-12 2012-06-06 优尼麦德药物股份有限公司 治疗或预防骨退化或骨质疏松症的方法
US8084446B2 (en) 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
JP2009519926A (ja) * 2005-12-16 2009-05-21 ライル コーポレート ディベロップメント インコーポレーテッド エストロゲンの非全身性膣投与による膣組織の再生
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
CA2702710C (en) 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
CA2860133C (en) 2011-12-29 2016-10-11 Universidad De Chile Vaginal ring comprising dhea or dhea sulphate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK122125B (da) * 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
JPS505372A (zh) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
DE2534911C2 (de) * 1975-08-01 1985-04-18 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 5-Androsten-17-on-Derivaten
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
SE8303031D0 (sv) * 1983-05-30 1983-05-30 Leo Ab Improved steroid esters preparation
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
WO1990006120A1 (en) * 1988-12-01 1990-06-14 Schering Corporation Compositions for transdermal delivery of estradiol
IE62715B1 (en) * 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására

Also Published As

Publication number Publication date
SK286664B6 (sk) 2009-03-05
CN101444519A (zh) 2009-06-03
CA2154161A1 (en) 1994-08-04
US5824671A (en) 1998-10-20
MY134585A (en) 2007-12-31
US5776923A (en) 1998-07-07
MY157883A (en) 2016-08-01
IL181018A (en) 2012-07-31
US5728688A (en) 1998-03-17
UA73911C2 (en) 2005-10-17
US5922700A (en) 1999-07-13
IL181017A0 (en) 2007-07-04
EP1382340B1 (en) 2006-04-05
CA2154161C (en) 2006-12-12
CN1954804A (zh) 2007-05-02
US5955455A (en) 1999-09-21
IL181019A0 (en) 2007-07-04
EP1382340A1 (en) 2004-01-21
US5780460A (en) 1998-07-14
IL181016A0 (en) 2007-07-04
IL181015A0 (en) 2007-07-04
IL181015A (en) 2012-12-31
CN102357247A (zh) 2012-02-22
DK1382340T3 (da) 2006-08-14
IL181018A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
ZA94372B (en) Therapeutic methods and delivery systems utilizing sex steroid precursors
EP0767685A4 (en) STENT AND THERAPEUTIC ADMINISTRATION SYSTEM
EP0702966A3 (en) Contrast medium delivery systems with patient specific dosage and methods
EP0802788A4 (en) NEW THERAPEUTIC DELIVERY SYSTEM
EP0707471A4 (en) NEW ADMINISTRATION SYSTEMS FOR ACTIVE SUBSTANCES
AU4370593A (en) Tissue-specific implantable therapeutic agent delivery system
AU4101693A (en) Subcutaneous implantable multiple agent delivery system
ZA918526B (en) Drug delivery system and method
HUP0104168A3 (en) Spray on bandage and drug delivery system
AU1029595A (en) Collagen-based injectable drug delivery system and its use
IL109661A0 (en) Drug delivery device
IL143087A0 (en) Drug delivery systems and methods
AU4473796A (en) Mixing and delivery system
AU1970495A (en) Drug delivery device and method of construction
GB9701904D0 (en) A system for the delivery of drugs and therapeutic agents
ZA9811086B (en) Delivery devices and their use
HK1005797A1 (en) Vaporizer and liquid delivery system using same
AU6226894A (en) Implantable therapy systems and methods
EP0855873A4 (en) CONDOM CATHETER AND SUPPORT DEVICES
EP0729370A4 (en) DEVICE AND METHOD FOR IONTOPHORETIC ADMINISTRATION OF MEDICINES
EP1019061A4 (en) UREASE-DEPENDENT ADMINISTRATION SYSTEMS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
ZA935575B (en) Therapeutic agent and its use.
EP0794769A4 (en) METHOD FOR DISPENSING DRUGS AND COATINGS FOR USE IN THIS METHOD
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
EP0862407A4 (en) TOPICAL FORMULATIONS AND ADMINISTRATION SYSTEMS